Journal of aerosol medicine and pulmonary drug delivery · 2025
Preclinical Studies of Clofazimine Inhalation Suspension: A Novel Formulation for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fares Wassim H, Castagna Michael, Hofmann Thomas
Аннотация
BACKGROUND: Clofazimine inhalation suspension is a novel formulation of clofazimine developed as a potential lung-targeted treatment for pulmonary nontuberculous mycobacteria disease.
METHODS: Safety and toxicokinetic parameters were assessed in 28-day, repeat-dose studies of up to 3.59 mg/kg/day clofazimine inhalation suspension in 8-week-old Sprague Dawley rats and up to 2.72 mg/kg/day in 5-7-month-old beagle dogs with 56-day recovery periods. A 6-month inhalation toxicity study without recovery was also conducted in beagle dogs, with daily doses up to 2.95 mg/kg for 182 days.
RESULTS: No adverse effects were observed, but minimal to mild nonadverse pulmonary changes were observed in high-dose treatment groups. The no-observed-adverse-effect levels were a sex-averaged 1.78 mg/kg in rats (28 days) and 2.73/2.95 mg/kg in male/female dogs (182 days). Median time to maximum concentration ranged from 6 to 12 hours and 0.5 to 6 hours in the rat and dog studies, respectively. Plasma area under the concentration-time curve from 0 to 24 hours and maximum plasma concentration increased dose-dependently and exhibited accumulation ratios ≥∼2 in both 28-day studies. Clofazimine concentrations in lung tissue were dose-dependent in all 3.
DISCUSSION: Clofazimine inhalation suspension was well tolerated at doses supporting multifold safety margins for the ongoing phase 3 ICoN-1 study. Lung concentrations exceeded the estimated minimum inhibitory concentration against Mycobacterium avium complex, even after 56 days of recovery.
METHODS: Safety and toxicokinetic parameters were assessed in 28-day, repeat-dose studies of up to 3.59 mg/kg/day clofazimine inhalation suspension in 8-week-old Sprague Dawley rats and up to 2.72 mg/kg/day in 5-7-month-old beagle dogs with 56-day recovery periods. A 6-month inhalation toxicity study without recovery was also conducted in beagle dogs, with daily doses up to 2.95 mg/kg for 182 days.
RESULTS: No adverse effects were observed, but minimal to mild nonadverse pulmonary changes were observed in high-dose treatment groups. The no-observed-adverse-effect levels were a sex-averaged 1.78 mg/kg in rats (28 days) and 2.73/2.95 mg/kg in male/female dogs (182 days). Median time to maximum concentration ranged from 6 to 12 hours and 0.5 to 6 hours in the rat and dog studies, respectively. Plasma area under the concentration-time curve from 0 to 24 hours and maximum plasma concentration increased dose-dependently and exhibited accumulation ratios ≥∼2 in both 28-day studies. Clofazimine concentrations in lung tissue were dose-dependent in all 3.
DISCUSSION: Clofazimine inhalation suspension was well tolerated at doses supporting multifold safety margins for the ongoing phase 3 ICoN-1 study. Lung concentrations exceeded the estimated minimum inhibitory concentration against Mycobacterium avium complex, even after 56 days of recovery.